Dako and Epitomics enter into strategic alliance on developing and launching IHC diagnostic monoclonal antibodies

03-23-2011: Dako Denmark A/S and Epitomics, Inc. announced that they have entered into a collaboration which will allow the companies to unite competencies to provide the Anatomic Pathology market with state-of-the-art antibodies.

Dako's expertise within the field of human cancer diagnostics, including development of new diagnostic antibodies relevant in identifying, differentiating and characterizing tumors, and Epitomics' exclusive intellectual property rights and expertise within development and production of rabbit monoclonal antibodies are the key ingredients to future development of routine diagnostics, prognostics and predictive immunohistochemical assays, also known as companion diagnostics or PharmacoDiagnostics (PharmDxTM).

Besides the development and launch of new state-of-the-art monoclonal antibodies the strategic alliance between Dako and Epitomics also includes a technology transfer from Epitomic's to Dako's facilities.

The financial terms of the agreement were not disclosed.

Contact / Request information

Request further information free of charge:

Facts, background information, dossiers
  • DAKO
More about Dako
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE